Edwards Lifesciences Corporation
EW
$86.67
-$0.08-0.09%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.37B | 1.08B | 1.11B | 1.10B | 1.09B |
| Total Depreciation and Amortization | 156.50M | 117.30M | 118.80M | 120.70M | 114.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.20M | 4.50M | -94.10M | -91.10M | -52.40M |
| Change in Net Operating Assets | -562.80M | -755.50M | -610.20M | -942.90M | -695.90M |
| Cash from Operations | 1.02B | 794.90M | 876.20M | 542.30M | 806.40M |
| Capital Expenditure | -212.60M | -155.10M | -191.20M | -200.50M | -239.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -298.20M | -298.20M | -298.20M | -298.20M | 46.00M |
| Divestitures | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Other Investing Activities | -580.50M | -210.20M | 122.80M | 109.90M | 395.00M |
| Cash from Investing | -1.09B | 2.04B | 2.34B | 2.31B | 2.90B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 170.40M | 135.70M | 132.80M | 145.00M | 149.60M |
| Repurchase of Common Stock | -852.90M | -314.20M | -466.80M | -158.40M | -606.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -234.30M | 1.80M | 8.00M | 7.10M | 9.00M |
| Cash from Financing | -916.80M | -1.15B | -1.30B | -983.00M | -1.42B |
| Foreign Exchange rate Adjustments | 2.70M | 3.70M | 62.70M | 90.10M | 35.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -988.60M | 1.63B | 1.92B | 1.91B | 2.27B |